Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Christine Lee, Anne Preston, Brooke Augustine, Charla Andrews, Galina V. Yamshchikov, Somia P. Hickman, Steven Schech, Jack Hutter, Paul T. Scott, Paige Waterman, Mihret F. Amare, Victoria Kioko, Casey Storme, Kayvon Modjarrad, Melanie McCauley, Merlin L. Robb, Martin R. Gaudinski, Ingelise J. Gordon, LaSonji A. Holman, Alicia T. Widge, Larisa Strom, Myra Happe, Josephine H. Cox, Sandra Vazquez, Daphne A. Stanley, Tamar Murray, Caitlyn N M Dulan, Ruth Hunegnaw, Sandeep Narpala, Phillip A. Swanson, Manjula Basappa, Jagada Thillainathan, Marcelino Padilla, Britta Flach, Sarah O’Connell, Olga Trofymenko, Patricia Morgan, Emily E. Coates, Jason G. Gall, Adrian B. McDermott, Richard A. Koup, John R. Mascola, Aurélie Ploquin, Nancy J. Sullivan, Julie A. Ake, Julie E. Ledgerwood, Rebecca Lampley, Brenda Larkin, Pamela Costner, Hope Wilson, Mike Read